| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Rajendra Prasad | |
| Deeksha Pal | |||
| Wajid Mohammad | |||
| P2860 | cites work | Hallmarks of Cancer: The Next Generation | Q22252312 |
| Specificity and stoichiometry of subunit interactions in the human telomerase holoenzyme assembled in vivo | Q24305098 | ||
| SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin | Q24310658 | ||
| Telomere protection by mammalian Pot1 requires interaction with Tpp1 | Q24319841 | ||
| Control of telomere length by the human telomeric protein TRF1 | Q24320111 | ||
| Telomere dysfunction and cell survival: roles for distinct TIN2-containing complexes | Q24336203 | ||
| POT1 and TRF2 cooperate to maintain telomeric integrity | Q24338505 | ||
| The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats | Q24339608 | ||
| Control of human telomere length by TRF1 and TRF2 | Q24554302 | ||
| RNA interference: biology, mechanism, and applications | Q24597695 | ||
| TERRA: telomeric repeat-containing RNA | Q24656014 | ||
| Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies | Q26744271 | ||
| Regulation of the Telomerase Reverse Transcriptase Subunit through Epigenetic Mechanisms | Q26744572 | ||
| An anchor site-type defect in human telomerase that disrupts telomere length maintenance and cellular immortalization | Q28116246 | ||
| Human telomerase activation requires two independent interactions between telomerase RNA and telomerase reverse transcriptase | Q28138478 | ||
| Secondary structure of vertebrate telomerase RNA | Q28138961 | ||
| The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes | Q28139460 | ||
| The histone deacetylase inhibitor trichostatin A derepresses the telomerase reverse transcriptase (hTERT) gene in human cells | Q45713501 | ||
| The Genetic Evolution of Melanoma from Precursor Lesions | Q46079642 | ||
| Inhibition of hTERT expression by MAP kinase inhibitor induces cell death in renal cell carcinoma. | Q50884246 | ||
| Epigenetic regulation of telomere length in mammalian cells by the Suv39h1 and Suv39h2 histone methyltransferases. | Q51598430 | ||
| Augmented telomerase activity, reduced telomere length and the presence of alternative lengthening of telomere in renal cell carcinoma: plausible predictive and diagnostic markers. | Q53584574 | ||
| TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA. | Q54347306 | ||
| Nano-Strategies to Fight Multidrug Resistant Bacteria-"A Battle of the Titans" | Q57177419 | ||
| Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalyti | Q58380161 | ||
| Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines | Q73851376 | ||
| Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body | Q78257210 | ||
| Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer | Q81482708 | ||
| Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia | Q83230375 | ||
| Cancer vaccination with telomerase peptide GV1001 | Q83709515 | ||
| Expression and clinical significance of COMPASS family of histone methyltransferases in clear cell renal cell carcinoma | Q89260124 | ||
| Telomere Loop Dynamics in Chromosome End Protection | Q90393979 | ||
| A chair-type G-quadruplex structure formed by a human telomeric variant DNA in K+ solution | Q91323666 | ||
| Reduction in H3K4me patterns due to aberrant expression of methyltransferases and demethylases in renal cell carcinoma: prognostic and therapeutic implications | Q92502665 | ||
| Antiadhesive effects of GRN163L--an oligonucleotide N3'->P5' thio-phosphoramidate targeting telomerase | Q40174226 | ||
| A G-quadruplex telomere targeting agent produces p16-associated senescence and chromosomal fusions in human prostate cancer cells | Q40503963 | ||
| Telomeric recombination in mismatch repair deficient human colon cancer cells after telomerase inhibition | Q40554439 | ||
| Telomere maintenance by recombination in human cells. | Q40839283 | ||
| Regulation mechanisms of mammalian telomerase. A review. | Q41703149 | ||
| Human telomerase RNA and box H/ACA scaRNAs share a common Cajal body-specific localization signal. | Q42057695 | ||
| Mutations of the TERT promoter are common in basal cell carcinoma and squamous cell carcinoma | Q42444688 | ||
| TERT promoter mutations in skin cancer: the effects of sun exposure and X-irradiation. | Q42456732 | ||
| Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma | Q43128951 | ||
| How shelterin solves the telomere end-protection problem | Q44220453 | ||
| A conserved WD40 protein binds the Cajal body localization signal of scaRNP particles | Q28238122 | ||
| Shelterin: the protein complex that shapes and safeguards human telomeres | Q28272546 | ||
| The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter | Q28293716 | ||
| Identification of a specific telomere terminal transferase activity in Tetrahymena extracts | Q28306745 | ||
| Super-resolution fluorescence imaging of telomeres reveals TRF2-dependent T-loop formation | Q28854371 | ||
| The Fusion of Broken Ends of Chromosomes Following Nuclear Fusion | Q28913702 | ||
| A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis | Q29614741 | ||
| Highly recurrent TERT promoter mutations in human melanoma | Q29614798 | ||
| TERT promoter mutations in familial and sporadic melanoma | Q29614920 | ||
| Structure and function of telomeres | Q29615759 | ||
| A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes | Q29617061 | ||
| Gene silencing in cancer in association with promoter hypermethylation | Q29617274 | ||
| Reverse transcriptase motifs in the catalytic subunit of telomerase | Q29618392 | ||
| Mutation in TERT separates processivity from anchor-site function | Q30446605 | ||
| Recent expansion of the telomeric complex in rodents: Two distinct POT1 proteins protect mouse telomeres | Q33250127 | ||
| Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1. | Q33293671 | ||
| Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect | Q33302426 | ||
| siRNA inhibition of telomerase enhances the anti-cancer effect of doxorubicin in breast cancer cells | Q33439232 | ||
| Epigenetic Regulation of Telomere Maintenance for Therapeutic Interventions in Gliomas. | Q33737472 | ||
| Molecular mechanisms of action of antisense drugs | Q33916100 | ||
| Functional multimerization of the human telomerase reverse transcriptase | Q33969441 | ||
| A critical stem-loop structure in the CR4-CR5 domain of mammalian telomerase RNA. | Q34012344 | ||
| The biogenesis and regulation of telomerase holoenzymes | Q34042917 | ||
| A physical and functional constituent of telomerase anchor site | Q34049648 | ||
| Alternative lengthening of telomeres in mammalian cells | Q34114656 | ||
| InTERTpreting telomerase structure and function | Q34146318 | ||
| Altered telomeres in tumors with ATRX and DAXX mutations | Q34196696 | ||
| TRF1 negotiates TTAGGG repeat-associated replication problems by recruiting the BLM helicase and the TPP1/POT1 repressor of ATR signaling | Q34518947 | ||
| The structure and function of telomerase reverse transcriptase | Q34535163 | ||
| Telomerase as a universal tumor-associated antigen for cancer immunotherapy | Q34535727 | ||
| Telomerase RNA structure and function: implications for dyskeratosis congenita. | Q34547087 | ||
| Telomere length regulates the epigenetic status of mammalian telomeres and subtelomeres | Q34604352 | ||
| TERT promoter mutations and gene amplification: promoting TERT expression in Merkel cell carcinoma | Q34654382 | ||
| Telomere length, stem cells and aging | Q34689235 | ||
| Developmentally regulated transcription of mammalian telomeres by DNA-dependent RNA polymerase II. | Q34729916 | ||
| The hTERTalpha splice variant is a dominant negative inhibitor of telomerase activity | Q34785876 | ||
| Corruption of the intra-gene DNA methylation architecture is a hallmark of cancer | Q34847813 | ||
| Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells. | Q35041364 | ||
| Ku acts in a unique way at the mammalian telomere to prevent end joining | Q35207184 | ||
| Ets2 maintains hTERT gene expression and breast cancer cell proliferation by interacting with c-Myc. | Q35676663 | ||
| A primary melanoma and its asynchronous metastasis highlight the role of BRAF, CDKN2A, and TERT | Q35751775 | ||
| The peptide nucleic acids (PNAs), powerful tools for molecular genetics and cytogenetics | Q35814990 | ||
| Therapeutic inhibition of TRF1 impairs the growth of p53-deficient K-RasG12V-induced lung cancer by induction of telomeric DNA damage | Q35904248 | ||
| TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas. | Q36413047 | ||
| Human Rap1 interacts directly with telomeric DNA and regulates TRF2 localization at the telomere | Q36451842 | ||
| Highlights in experimental therapeutics | Q36463460 | ||
| Telomere uncapping by the G-quadruplex ligand RHPS4 inhibits clonogenic tumour cell growth in vitro and in vivo consistent with a cancer stem cell targeting mechanism | Q36610311 | ||
| Telomerase inhibition in cancer therapeutics: molecular-based approaches | Q36638624 | ||
| Prospects and challenges of building a cancer vaccine targeting telomerase | Q36918394 | ||
| Physiological assembly and activity of human telomerase complexes | Q37022486 | ||
| High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions | Q37064910 | ||
| Strategies targeting telomerase inhibition | Q37067685 | ||
| Telomerase and cancer therapeutics | Q37078833 | ||
| Telomere elongation involves intra-molecular DNA replication in cells utilizing alternative lengthening of telomeres | Q37112118 | ||
| Defining the molecular mechanisms of human cell immortalization | Q37173111 | ||
| Genetic and epigenetic background and protein expression profiles in relation to telomerase activation in medullary thyroid carcinoma | Q37225274 | ||
| TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine | Q37663771 | ||
| Targeting the telomere and shelterin complex for cancer therapy: current views and future perspectives. | Q37825614 | ||
| Novel anticancer therapeutics targeting telomerase | Q38030204 | ||
| Human telomerase reverse transcriptase motifs required for elongation of a telomeric substrate. | Q38348979 | ||
| Replicating through telomeres: a means to an end. | Q38549970 | ||
| Mutations in the promoter of the telomerase gene TERT contribute to tumorigenesis by a two-step mechanism | Q38619216 | ||
| hTERT knockdown in human embryonic kidney cells using double-stranded RNA | Q39025568 | ||
| RNA interference using a plasmid construct expressing short-hairpin RNA | Q39025712 | ||
| Frequency of TERT promoter mutations in human cancers | Q39120274 | ||
| Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss | Q39139952 | ||
| Telomere length regulates TERRA levels through increased trimethylation of telomeric H3K9 and HP1α. | Q39291071 | ||
| Functional multimerization of human telomerase requires an RNA interaction domain in the N terminus of the catalytic subunit | Q39677546 | ||
| The C terminus of the human telomerase reverse transcriptase is a determinant of enzyme processivity | Q39792077 | ||
| Telomerase inhibition by synthetic nucleic acids and chemosensitization in human bladder cancer cell lines | Q39998080 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 135-146 | |
| P577 | publication date | 2020-03-10 | |
| P1433 | published in | Indian journal of clinical biochemistry | Q26853918 |
| P1476 | title | Therapeutic Targets in Telomerase and Telomere Biology of Cancers | |
| P478 | volume | 35 |
Search more.